“Chronic pancreatitis is a chronic inflammatory destructive disease of the pancreas associated with multiple consequences including exocrine pancreatic insufficiency. Establishing a community portal for patients with exocrine pancreatic insufficiency due to chronic pancreatitis will help patients in many ways, including: identifying symptoms, improving communication with other patients with similar conditions, and improving patient care,” said Dr. Samer AlKaade, MD, Mercy Clinic Gastroenterology, advanced endoscopy, St. Louis, Missouri, UNITED STATES.
Mission: Cure is a non-profit organization working to improve the lives of people with pancreatitis and find effective therapies for the disease. The community will be administered and hosted by Mission: Cure – the organization will share valuable patient education resources as well as their progress towards a cure for chronic pancreatitis. Golden Megane, CEO and co-founder of Mission: Cure, said: “For patients, the community will be a place where you can come and talk about the health issues that affect you – whether you have chronic pancreatitis, acute pancreatitis or related conditions like exocrine pancreatic insufficiency – also known as of IPE.”
By coming to the community, people will also benefit from HealthUnlocked technology, which makes personalized health-related recommendations, directs people to helpful information, connects them with others, and highlights research that may help them. to interest.
“Aimmune is committed to better understanding the impact of EPI on the quality of life of patients with chronic pancreatitis”, noted mohamed yassine, MD. SVP, Global Medical Affairs for Aimmune Therapeutics. This community is a distinct additional opportunity outside of the traditional PACT-CP registry, offered by Aimmune Therapeutics, to learn from patients in their own words about how acute and chronic pancreatitis affects their lives.
Aimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing pharmaceutical therapies to prevent, manage and treat diet and metabolism-related diseases, including pancreatic exocrine insufficiency. Aimmune markets Pancreatic Enzyme Replacement Therapy (PERT), an FDA and EU approved drug for peanut allergy and other investigational therapies in development.
HealthUnlocked is an innovative social health network of over 1.4 million patients, representing over 250 disease states and conditions with over 300 patient advocacy groups. These patients share treatment paradigms, symptom management and quality of life issues globally. HealthUnlocked is owned by CorEvitas, LLC, within its patient experience unit, HealthiVibe. Clinicians, the NHS (including NHS Choices), insurers and industry can use HealthUnlocked to securely connect with patients online.
Contact: Golden Megane, Mission: Heal
E-mail: [email protected]
Call: +1 401 375-2873
SOURCE Mission: Heal